The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
Adenosine receptors as drug targets — what are the challenges?
Open accessAbstract
Adenosine signalling has long been a target for drug development, with adenosine itself or its derivatives being used clinically since the 1940s. In addition, methylxanthines such as caffeine have profound biological effects as antagonists at adenosine receptors. Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors. There is strong evidence that adenosine has a functional role in many diseases, and several pharmacological compounds specifically targeting individual adenosine receptors — either directly or indirectly — have now entered the clinic. However, only one adenosine receptor-specific agent — the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) — has so far gained approval from the US Food and Drug Administration (FDA). Here, we focus on the biology of adenosine signalling to identify hurdles in the development of additional pharmacological compounds targeting adenosine receptors and discuss strategies to overcome these challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Hart, M. L., Grenz, A., Gorzolla, I. C., Schittenhelm, J., Dalton, J. H., & Eltzschig, H. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903617 · Cited by 121
Self-citationRetractedHart, M. L., Gorzolla, I. C., Schittenhelm, J., Dalton, J. H., & Eltzschig, H. K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700997 · Cited by 116
Self-citationRetractedGrenz, A., Bauerle, J. D., Dalton, J. H., Ridyard, D. G., Badulak, A., Tak, E., McNamee, E. N., Clambey, E. T., Moldovan, R., Reyes, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60214 · Cited by 106
Self-citationRetractedInternational Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382
Self-citationFredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Self-citationInternational Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Self-citationEltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Self-citationThe 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Cited by
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Chromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Clark, I., & Landolt, H. P. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.01.006 · Cited by 499
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Boison, D., & Yegutkin, G. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.007 · Cited by 336
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Ohta, A., & Sitkovsky, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00304 · Cited by 320
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
Yegutkin, G. G. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953627 · Cited by 299
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Effects of caffeine on the human circadian clock in vivo and in vitro
Burke, T. M., Markwald, R. R., McHill, A. W., Chinoy, E. D., Snider, J. A., Bessman, S. C., Jung, C. M., O’Neill, J. S., & Wright, K. P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5125 · Cited by 283
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
Glukhova, A., Thal, D. M., Nguyen, A. T., Vecchio, E. A., Jörg, M., Scammells, P. J., May, L. T., Sexton, P. M., & Christopoulos, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.042 · Cited by 275
The Role of the Phosphorus Atom in Drug Design
Rodriguez, J. B., & Gallo‐Rodriguez, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201800693 · Cited by 267
Medicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Dessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201
Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives
Reichert, C. F., Deboer, T., & Landolt, H. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13597 · Cited by 183
“Although adenosine receptors have long been recognised as possible therapeutic targets for the pharmacological treatment of sleep disturbances (Chen et al., 2013; Jacobson & Gao, 2006), no approved drugs to ameliorate disturbed wakefulness and sleep by specifically targeting the adenosine…”
BackgroundKetogenic diet prevents epileptogenesis and disease progression in adult mice and rats
Lusardi, T. A., Akula, K. K., Coffman, S. Q., Ruskin, D. N., Masino, S. A., & Boison, D. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.007 · Cited by 155
Naviaux, J. C., Schuchbauer, M. A., Li, K., Wang, L., Risbrough, V. B., Powell, S. B., & Naviaux, R. K. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.33 · Cited by 134
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation
Poupon, R. (2015) · Hepatology · doi:10.1002/hep.27715 · Cited by 120
Rapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120
Adenosine receptor neurobiology: overview
Chen, J.-F., Lee, C.-F., & Chern, Y. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00001-5 · Cited by 119
Wang, M., Li, P., Li, Z., da Silva, B. S., Zheng, W., Xiang, Z., He, Y., Xu, T., Cordeiro, C., Deng, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37601-x · Cited by 73
Self-citationAntihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73
Adenosine and Adenosine Receptor-Mediated Action in Coronary Microcirculation
Zhang, Y., Wernly, B., Cao, X., Mustafa, S. J., Tang, Y., & Zhou, Z. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00859-7 · Cited by 71
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Ehlen, Q. T., Costello, J. P., Mirsky, N. A., Slavin, B. V., Parra, M., Ptashnik, A., Nayak, V. V., Coelho, P. G., & Witek, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c01279 · Cited by 29
Luo, M.-L., Zhao, Q., He, X.-H., Xie, X., Zhu, H.-P., You, F.-M., Peng, C., Zhan, G., & Huang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114574 · Cited by 25
RetractedBiocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21
Lowe, P. T., Dall'Angelo, S., Mulder‐Krieger, T., IJzerman, A. P., Zanda, M., & O'Hagan, D. (2017) · ChemBioChem · doi:10.1002/cbic.201700382 · Cited by 19
Marchi, E., Muraca, I., Berteotti, M., Gori, A. M., Valenti, R., & Marcucci, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115852 · Cited by 8
Liu, Y., & Gong, F. (2025) · Phytotherapy Research · doi:10.1002/ptr.8415 · Cited by 6
Metadata
- Authors
- Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03-28
- Volume
- 12
- Issue
- 4
- Pages
- 265-286
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1975391500
- Cited by
- 895
- References
- 287
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.